Keyword Search
 

2018 | 2017 | 2016 | 2015 | 2014
Ocular Therapeutix, Inc. (Nasdaq: OCUL) to Ring The Nasdaq Stock Market Opening Bell

Ocular Therapeutix™ Announces Encouraging Top-Line Results from Exploratory Phase 2 Trial for DEXTENZA™ in Patients with Inflammatory Dry Eye Disease

Ocular Therapeutix™ Announces FDA Acceptance of NDA Filing for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain

Ocular Therapeutix™ Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis

Ocular Therapeutix™ to Present at the Piper Jaffray 27th Annual Healthcare Conference

Ocular Therapeutix™ Reports Third Quarter 2015 Financial Results

Ocular Therapeutix™ Expands Its Board of Directors with the Election of Industry Leader W. James O’Shea

Ocular Therapeutix™ to Report Third Quarter 2015 Financial Results

Ocular Therapeutix™ to Participate in Three Conferences in November 2015

Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis

Ocular TherapeutixTM Reports on Topline Results of Phase 2b Glaucoma Clinical Trial

Ocular Therapeutix™ Begins Enrollment in Third Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Post-Surgical Ocular Inflammation and Pain

Ocular Therapeutix™ Submits New Drug Application to U.S. Food and Drug Administration for DEXTENZA® for the Treatment of Post-Surgical Ocular Pain

Ocular Therapeutix Expands Its Board of Directors with the Appointment of Renowned Retinal Specialist Jeffrey S. Heier, M.D.

Ocular Therapeutix™ to Participate in Two Investor Conferences in September 2015

Ocular Therapeutix™ Reports Second Quarter 2015 Financial Results

Ocular Therapeutix™ to Report Second Quarter 2015 Financial Results

Ocular Therapeutix™ to Participate at the Cantor Fitzgerald Inaugural Healthcare Conference

Ocular Therapeutix™ Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis

Ocular Therapeutix, Inc. Announces Pricing of Public Offering of Common Stock

Ocular Therapeutix, Inc. Announces Proposed Public Offering of Common Stock

Ocular Therapeutix™ Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results

Ocular Therapeutix™ to Report First Quarter 2015 Financial Results

Ocular Therapeutix to Present Eight Posters Highlighting its Sustained Release Hydrogel Platform Technology at the Association for Research in Vision and Ophthalmology Annual Meeting

Ocular Therapeutix™ Reports Topline Clinical Data for its Second Phase 3 Clinical Trial Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and Pain

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2014 Financial Results

Ocular Therapeutix™ Reports Positive Topline Clinical Data for the First of Two Phase 3 Clinical Trials Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and Pain

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2014 Financial Results

Ocular Therapeutix™ to Participate in Two Upcoming Investor Conferences

Ocular Therapeutix™ to Present at the 17th Annual BIO CEO & Investor Conference

Ocular Therapeutix™ Enrolls First Patient in Phase 2 Clinical Trial for Sustained Release Dexamethasone for the Treatment of Dry Eye Disease